AvoMed
Biowaste-based Bioactive Compound for Dermal Disorders
Health Tech & Life Sciences
Non Active, Dec 2022 ceased to operate
Company Overview
Snapshot
Founded in June 2016, AvoMed operated with 1–10 employees and secured funding across one round from one investor. The company ceased operations in December 2022.
Business overview
AvoMed specializes in the Health Tech & Life Sciences sector, focusing on the development and manufacturing of AvoMed PFA, a patented bioactive compound. This compound is extracted from avocado pits, transforming biowaste into an active ingredient for personal care products and treatments for dermal disorders such as psoriasis and atopic dermatitis. The company's technology is designed to repair skin damage caused by UV radiation, pollution, aging, and other stressors, serving the cosmetics and healthcare industries.
Log in to access full profile ›Company Intelligence Q&A
- What is AvoMed PFA?
- AvoMed PFA is a patented bioactive compound extracted from avocado pits (biowaste) that serves as an active ingredient to enhance personal care products and treat dermal disorders like psoriasis and atopic dermatitis.
- What is the primary application of AvoMed's technology?
- AvoMed's technology focuses on developing and manufacturing AvoMed PFA for use in topical cosmetic products to treat skin damage and inflammatory disorders, including damage from UV radiation, pollution, and aging.
- When did AvoMed cease operations?
- AvoMed ceased to operate in December 2022.
- What was the company's status as of December 2022?
- As of December 2022, AvoMed was non-active and had ceased to operate.